v3.25.4
Other (Income)/Deductions—Net - Schedule of Additional Information About Intangible Assets Impaired (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Intangible assets, fair value [1] $ 4,585    
Intangible asset impairments $ 4,940   $ 3,000
Intangible Asset, Statement Of Income Or Comprehensive Income Extensible Enumeration, Not Disclosed Flag Consolidated Statements of Operations Consolidated Statements of Operations  
Impairment, Intangible Asset, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag Consolidated Statements of Operations    
Developed Technology Rights [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Finite-lived [1],[2] $ 185    
Intangible asset impairments [2] 560    
Brand [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Finite-lived [1],[2] 0    
Intangible asset impairments [2] 240    
Licensing Agreements [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Finite-lived [1],[2] 0    
Intangible asset impairments [2] 27    
IPR&D [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
IPR&D [1],[2] 4,400    
Intangible asset impairments [2] 3,903    
Licensing Agreements [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
IPR&D [1],[2] 0    
Intangible asset impairments [2] 210    
Level 1 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Intangible assets, fair value [1] 0    
Level 1 [Member] | Developed Technology Rights [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Finite-lived [1],[2] 0    
Level 1 [Member] | Brand [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Finite-lived [1],[2] 0    
Level 1 [Member] | Licensing Agreements [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Finite-lived [1],[2] 0    
Level 1 [Member] | IPR&D [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
IPR&D [1],[2] 0    
Level 1 [Member] | Licensing Agreements [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
IPR&D [1],[2] 0    
Level 2 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Intangible assets, fair value [1] 0    
Level 2 [Member] | Developed Technology Rights [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Finite-lived [1],[2] 0    
Level 2 [Member] | Brand [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Finite-lived [1],[2] 0    
Level 2 [Member] | Licensing Agreements [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Finite-lived [1],[2] 0    
Level 2 [Member] | IPR&D [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
IPR&D [1],[2] 0    
Level 2 [Member] | Licensing Agreements [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
IPR&D [1],[2] 0    
Level 3 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Intangible assets, fair value [1] 4,585    
Level 3 [Member] | Developed Technology Rights [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Finite-lived [1],[2] 185    
Level 3 [Member] | Brand [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Finite-lived [1],[2] 0    
Level 3 [Member] | Licensing Agreements [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Finite-lived [1],[2] 0    
Level 3 [Member] | IPR&D [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
IPR&D [1],[2] 4,400    
Level 3 [Member] | Licensing Agreements [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
IPR&D [1],[2] $ 0    
[1] The fair value amounts reflect the remaining fair value for the assets that have been impaired as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1E.
[2] Reflects intangible assets written down to fair value in 2025. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; and assumptions about the probability of technical and regulatory success (PTRS) of ongoing clinical trials, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.